Immunoglobulins Market Analysis: $22.51 Billion Market Size In 2026 And Future Growth Prospects
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Immunoglobulins Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The immunoglobulins market has seen rapid expansion over recent years. This market is projected to expand from $20.32 billion in 2025 to $22.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.8%. Factors contributing to this historical growth include the rising incidence of immunodeficiency diseases, a surge in autoimmune disorder cases, enhancements in hospital infrastructure, progress in plasma fractionation technologies, and increasing recognition of antibody-based therapies.
The immunoglobulins market is projected to experience substantial expansion in the coming years. It is anticipated to reach a valuation of $34.52 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.3%. This anticipated growth throughout the forecast period stems from factors such as progress in personalized medicine, the creation of new monoclonal antibodies, an increase in home-based subcutaneous treatments, the proliferation of biotechnology and research facilities, and rising government backing for immunotherapy initiatives. Key trends for the forecast duration encompass personalized immunoglobulin therapies, a growing embrace of subcutaneous delivery techniques, heightened demand for IVIG in autoimmune conditions, the broadening of treatments for rare immunodeficiencies, and an increase in monoclonal antibody research.
Get A Free Sample Report With In-Depth Market Insights:
Immunoglobulins Market Growth Momentum: What Factors Are Shaping Demand?
The growth of the hyperphosphatemia treatment market is anticipated to be propelled by increasing healthcare expenditure. Hyperphosphatemia treatments involve therapies and medications designed to lower elevated phosphate levels in the blood, a common issue for patients with chronic kidney disease and other related conditions. Higher healthcare spending facilitates broader access to these treatments, supports the research and development of advanced therapies, and improves patient management strategies. For example, in November 2023, the Canadian Institute for Health Information, based in Canada, projected that total health spending in Canada would reach $344 billion in 2023, equivalent to $8,740 per person. This indicates a 2.8% increase compared to 2022, significantly higher than the 1.5% growth in health spending observed in 2022, highlighting a substantial resurgence in healthcare investment. Therefore, the expanding healthcare expenditure is a primary driver for the hyperphosphatemia treatment market’s growth.
Immunoglobulins Market Segmentation: How Does The Market Break Down By Category?
The immunoglobulins market covered in this report is segmented –
1) By Product: IGG, IGA, IGM, IGE, IGD
2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications
Subsegments:
1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)
2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA
3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM
4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE
5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD
Immunoglobulins Market Trends Redefining Industry Growth
Leading firms within the immunoglobulins market are innovating products like intravenous immunoglobulins to expand their customer reach, boost sales, and enhance revenue. For example, in September 2024, GC Biopharma, a biotechnology company based in South Korea, introduced ALYGLO (Immune Globulin Intravenous, Human-stwk) 10% Liquid into the U.S. market. This product is intended for managing primary humoral immunodeficiency (PI) in adults aged 17 years and older and is now accessible to patients via specialty pharmacies. This launch holds considerable importance because the U.S. constitutes the world’s largest immunoglobulin market, estimated at approximately $11.6 billion. GC Biopharma projects ALYGLO sales of $50 million in its initial year, with ambitions to elevate this sum to $300 million by 2028. Their ambitious growth plan includes collaborations with prominent U.S. pharmacy benefit managers and specialty pharmacies, which are vital for the efficient distribution of immunoglobulin products.
Immunoglobulins Market Competitive Overview And Top Companies
Major companies operating in the immunoglobulins market are Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited
View The Full Immunoglobulins Market Report:
Immunoglobulins Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the immunoglobulins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
